

# Insomnia

## *Clinically proven natural alternatives for treating insomnia*

CURT HENDRIX, M.S., C.C.N., C.N.S.

*Evidence-Based Use of Supplements*

### ABSTRACT

Sleep is required for human life, enabling critical functions such as those involved in cellular regulation and repair, detoxification, immune health, and hormone level modulation.<sup>1–4</sup> Our physiological homeostasis depends on sleep, yet according to the Centers for Disease Control and Prevention (CDC), one in three adults in the United States does not get enough of it.<sup>5</sup> Given the inextricable linkage between sleep and health, the CDC has warned about the health risks of inadequate sleep, and federal and industry dollars continue to fund research that can help elucidate the roles of sleep in disease and quality of life and to provide solutions for those who struggle with poor sleep. This paper provides an overview of the effects of sleep duration and sleep quality on health and proposes natural ways to prevent illness and chronic disease that may occur in part due to sleep disturbances through the strategic use of oral supplements.

### POOR SLEEP PATTERNS CAN BE DETRIMENTAL TO HEALTH

Much of what we know about the benefits of sleep comes from observations and studies of the detrimental effects of sleep deprivation and unhealthy sleep patterns. Accidents are one clear short-term consequence of inadequate sleep. Lack of sleep increases the risk of driving accidents, on-the-job accidents, and accidents in the home.<sup>6–8</sup> However, failing to establish regular, healthy sleep patterns can also lead to chronic disease and disabling symptoms.

Developing and maintaining healthy sleep habits may empower people to reduce their risks of illness and disease. Indeed, poor sleep is associated not only with greater risk for developing a host of health problems, including cardiovascular disease, stroke, neurodegenerative diseases, type 2 diabetes, and attention deficit hyperactivity disorder (ADHD), but also with a greater risk for suffering debilitating symptoms like migraine headaches and for living a shorter lifespan.<sup>9–16</sup>

#### Sleep and Cardiovascular Disease

Sleep habits have long been linked to cardiovascular and metabolic disease, including hypertension, atherosclerosis, heart failure, and sudden death.<sup>17</sup> Indeed, certain sleep disorders, such as obstructive sleep apnea, have been shown not only to correlate with but to cause systemic hypertension.<sup>18</sup> Research into the specific relationship between sleep and cardiovascular health suggests that short sleep duration could result in adverse cardiovascular events as a consequence of the enhanced blood pressure and sympathetic nervous system activity that occurs in response to sleep deprivation.<sup>19</sup> In addition to short sleep duration, poor sleep quality is also associated with an enhanced risk of coronary heart disease.<sup>20</sup> Given that sleep duration and quality are modifiable risks, researchers suggest that interventions to improve sleep should be pursued as potential strategies for reducing risk of cardiovascular disease.<sup>21</sup>

#### Sleep and Stroke

Research on the relationship between sleep and stroke incidence has revealed a U-shaped relationship wherein too much and too little sleep are each associated with a higher risk of stroke in both men and women, as are sleep

disturbances.<sup>22,23</sup> Sleep disorders like sleep apnea are linked to stroke. Though the relationship is complex, as sleep-disordered breathing occurs as both a risk factor for and a consequence of stroke, sleep is considered a potentially modifiable risk factor for vascular disease.<sup>12,24</sup> Rapid-eye movement (REM) sleep behavior disorder is also associated with a higher risk of both ischemic and hemorrhagic stroke.<sup>25</sup>

As a result of growing knowledge on the impact of sleep on stroke risk, experts urge people to find ways to get the appropriate amount of sleep and emphasize the need for more awareness about the importance of sleep duration and quality on this leading cause of death.<sup>26</sup>

#### Sleep and Neurodegenerative Disease

One degenerative disease for which there is a growing wealth of research into the role of sleep is the neurodegenerative disease, Alzheimer's. Alzheimer's disease is the most prevalent cause of dementia in the older population, accounting for 65 to 70% of the cases. The formation of amyloid- $\beta$  (also known as beta amyloid or A $\beta$ ) plaques and neurofibrillary tangles are the hallmarks of the disease. People with healthy sleep habits are at a lower risk for developing Alzheimer's disease and other forms of dementia.<sup>10</sup> Those at lower risk are those who do not suffer from insomnia and who do not experience sleep disordered breathing (SDB), which includes snoring, sleep apnea, and obstructive sleep apnea. The specific role that sleep plays in protecting against dementia is unclear, but studies have shown that insomnia increases both the production and secretion of amyloid- $\beta$ , leading to higher levels of amyloid- $\beta$  in those with insomnia as compared to those with healthy sleep patterns.<sup>27</sup>

Research showing that cerebrospinal levels of amyloid- $\beta$  and its precursor, amyloid precursor protein (APP), are higher at night suggest that it is during sleep that the brain clears itself of these substances.<sup>28</sup> These findings offer some insight into why sleep seems to protect against neurodegenerative diseases like Alzheimer's.

#### Sleep and Type 2 Diabetes

The amount of sleep people get has been shown to relate to adiposity, with shorter duration of nightly sleep often found to be associated with higher levels of adiposity, as well as a

higher likelihood of developing diabetes.<sup>29</sup> This relationship, however, may be more complex, as some studies have found that both low and high duration sleep are associated with an increased risk for type 2 diabetes, whereas a sleep duration of 7 to 8 hours per night is associated with the lowest risk for developing the disease.<sup>30</sup> Recent research suggests that those with or at risk of type 2 diabetes likely experience a positive feedback loop that leads them to engage in excessive sleep.<sup>31</sup>

In addition to sleep duration, sleep architecture may play a role in diabetes risk. For instance, slow wave sleep and rapid eye movement suppression have been shown to be correlated with insulin resistance, and those with type 2 diabetes are more likely to experience altered sleep structure.<sup>32,33</sup> Poor sleep quality is also associated with higher HbA1c, a hemoglobin test for diabetes and is thought to play a role in impaired glycemic control.<sup>34,35</sup> Sleep disorders such as obstructive sleep apnea have been shown to be associated with type 1 diabetes and gestational diabetes as well.<sup>36</sup>

### Sleep and Migraine

Migraines and other forms of headache can be associated with a variety of diseases and conditions, but they are also known to be associated with lack of sleep. Though the relationship between sleep and migraine is complex,<sup>37</sup> it is clear that the two often co-occur. Indeed, disturbed sleep is more common in adults and children with migraine than those without migraine, with between 30% and 50% of migraine patients experiencing disturbed sleep or poor sleep quality.<sup>38–41</sup> Further, the severity and prevalence of sleep problems increase proportionally with headache frequency, such that the vast majority of chronic migraineurs (68% to 84%) suffer from insomnia on a near-daily basis.<sup>38</sup>

There is evidence that lack of sleep causes migraines and that, conversely, migraines cause loss of sleep. It is therefore likely that migraineurs with disturbed sleep experience a negative feedback loop where migraines and loss of sleep reinforce one another and relief from either condition becomes harder and harder.<sup>38–40</sup> Nonetheless, restful sleep has been shown to be effective in relieving migraine attacks, strongly suggesting that insufficient sleep causes or exacerbates migraine headaches.

Consistent with this view is the finding that those with migraines are less likely to possess the ability to flexibly adapt their sleep/wake cycles<sup>42</sup> and are thus more likely to become sleep deprived. Even more telling is that lack of sleep is the most commonly reported trigger of headaches.<sup>43,44</sup>

### Sleep and ADHD

ADHD often co-occurs with sleep disorders such as obstructive sleep apnea, peripheral limb movement disorder, restless leg syndrome, and circadian-rhythm sleep disorders.<sup>45</sup> Research has found that adults with ADHD take longer to fall asleep, or in other words, have a longer sleep latency, than those without ADHD and also tend to wake up later.<sup>46</sup>

Perhaps unsurprisingly, interventions that promote healthy sleep in children with ADHD have been shown to reduce ADHD symptoms.<sup>47</sup> Interestingly, sleep duration also appears to interact with treatments, with the potential to improve response to medication.<sup>48</sup>

## STRATEGIES FOR IMPROVING SLEEP DURATION AND QUALITY

### Pharmacological Intervention

There are a number of prescription drugs that are used to

**help people sleep, but each comes with critical limitations.**

### *Antidepressants*

While antidepressants including selective serotonin reuptake inhibitors are sometimes used to improve sleep, the improvement they confer appears to be small and effective only in the short-term. The tolerability and safety of antidepressants to help with sleep is also uncertain.<sup>49</sup>

### *Benzodiazepines*

There is some evidence to suggest that benzodiazepines can help certain patients with insomnia and that they may be safe.<sup>50</sup> However, due to the long half-life of these drugs, they often lead to next day fatigue, as well as neuropsychological dysfunction.<sup>51</sup> Perhaps more concerning is that benzodiazepines are associated with drug dependence, withdrawal, and rebound symptoms.

### *Antihistamines*

Most over-the-counter drugs for insomnia are antihistamines, which are known to contain sedative properties. Unfortunately, people tend to quickly develop a tolerance to antihistamines, minimizing their efficacy for improving sleep. Antihistamines are also associated with adverse side effects including dry mouth, constipation, and confusion.<sup>52</sup>

### Alternative Treatments for Sleep

Alternative treatments for insomnia and disordered sleep include background music, acupuncture, prayer, deep breathing, meditation, yoga and massage. Natural supplements for sleep are another way to avoid the serious side effects of prescription drugs, and there is mounting evidence for the value of several natural ingredients, including:

### *Hops extract*

The sedative power of Hops extract has long been recognized and is associated with over 30 years of traditional medicinal use in Europe. Recently, it has been suggested that its acids, essential oil, and other constituents, such as xanthohumol, may play important roles in the sedative effect of Hops preparations.<sup>53</sup>

The results of clinical studies suggest that Hops extract may help to improve sleep quality, shorten time to fall asleep, improve sleep brain wave patterns, and improve subjective measures of restfulness after waking.<sup>54–59</sup> One study has provided some clarification on how Hops extract may confer its sleep benefits, suggesting that Hops may improve the ability to fall asleep by reducing anxiety.<sup>60</sup> In this study, pure Hops extract in a non-alcoholic beer (0.00% alcohol, 333 milliliters (ml) containing 0.3% or 100 milligrams (mg) of Hops) was administered to a work-stressed population of healthy female nurses in rotating night shifts to measure the sedative effect of hops on their sleep and wake rhythm patterns.

Overnight sleep parameters were assessed by an actigraph for fourteen days, and the hops extract was given with dinner. The sleep data were compared with subjects' base data, which had been collected before Hops consumption began.<sup>60</sup>

Actigraphy demonstrated not only an improvement in overall sleep quality but a specific improvement in sleep latency. Specifically, those taking the Hops extract experienced a reduction in sleep latency, falling asleep more quickly. Compared to 21 minutes before using the Hops extract, those taking the Hops extract fell asleep on average within 12 minutes. These individuals also showed reductions in self-reported levels of anxiety.

The effective therapeutic dose of Hops for improved sleep parameters is 60 to 100 mg based on the above-cited human trial. Any sleep formula with less than 60 mg. of Hops extract would have been considered an inadequate dose.<sup>60</sup>

In addition to its ability to aid in sleep, Hops extract has numerous other health benefits, including stimulating the production of antioxidant enzymes, protecting DNA against mutations, protecting against thrombosis formation, which refers to the formation of blood clots, and protecting against benzopyrene and other dietary carcinogens.<sup>61–63</sup>

#### Valerian extract

Valerian, *valeriana officinalis*, is a perennial herb native to North America, Asia, and Europe and is used for its sedative and hypnotic properties. Multiple preparations are available, and the herb is commonly combined with other herbals, primarily Hops extract. Double-blind, placebo-controlled research has demonstrated that adults who take valerian for two weeks judge their sleep as better than those who take placebo. According to study subjects, this higher sleep quality is due to fewer night awakenings and greater sleep duration (Table 1).<sup>64</sup>

The appropriate dosage of Valerian has not been established conclusively but The European Medicines Agency (EMA) final proposal recommends a single dose of two to three grams (of dried herb) one half to one hour before bedtime with an earlier dose during the evening if necessary. Based on human trial data, a total serving size of 400 to 500 mg of Valerian extract would be considered an adequate dose of Valerian extract for a sleep supplement.

In addition to its positive effects on sleep duration and night awakenings, Valerian also has several other uses. It is used to treat anxiety, depression, menopausal symptoms, and stress and is among the eight most widely used herbal supplements in the world.<sup>65,66</sup>

#### Zizyphus Jujube extract

The Zizyphus jujuba seed extract, also known by its Chinese name, suanZaorentang, is the herb most frequently used for insomnia in China.<sup>67</sup> In Taiwan, it is the second most prescribed phytomedicine to treat insomnia.<sup>68</sup> The effect of Zizyphus jujube seeds on insomnia is clinically comparable to what is observed with benzodiazepines, the primary medical treatment for insomnia and other sleep disorders in primary care practice. Unlike benzodiazepines, however, Zizyphus has no withdrawal side effects.

Zizyphus spinosa is a varietal of Zizyphus jujube, and its impact on sleep is likely related to its stimulation of the inhibitory neurotransmitter, GABA, and its influence on serotonin receptors in the brain.<sup>67,69</sup> Suanzaorentang may also benefit sleep through sedative-hypnotic effects and its anxiolytic (anti-anxiety) properties, which are comparable to those of diazepam, a benzodiazepine drug.<sup>70</sup> Indeed, research on this substance has shown that, compared to placebo, it improves, to a greater extent, all ratings of sleep quality in insomniac patients.<sup>71</sup> The Zizyphus jujube seed extract effective dose for insomnia is 100 mg to 200 mg. Thus, any amount less than that would be inadequate for achieving the desired effects of relaxation or sleep in any formula. In addition to its use for insomnia, the seed of Zizyphus jujuba spinosa variety has also been used to treat psychiatric disorders in both Korean and Traditional Chinese Medicine (TCM). Its advantageous impact on sleep could also account for additional neuroprotective characteristics of Zizyphus jujube seed extract that have recently been observed. Specifically, the extract has been shown to mitigate memory loss associated with most neurological diseases and to block amyloid  $\beta$ -induced memory deficits in a mouse model of Alzheimer's disease.<sup>72</sup>

	Valerian Group	Placebo Group
Improvement in sleep duration	30.2%	22.7%
Improvement in night awakenings	15.8%	9.9%

Table 1. Impact of valerian extract on sleep. Adapted from: Oxman, A, Flottorp, S, Håvelsrud, K, Fretheim, A. et al. PLoS One. 2007; 2(10): e1040.

#### Glycine

Early research on glycine and its essential role in sleep was published in 1989.<sup>73</sup> Later, in 2008, one of the ways in which glycine aids in sleep was clarified when it was discovered that glycine is responsible for the profound muscle relaxation that occurs during various stages of REM sleep.<sup>74</sup>

The first clinical trial using glycine supplementation found that people who were given glycine before bedtime reported significantly reduced feelings of fatigue the following morning when compared to those who were given placebo. This study employed 19 subjects ranging from 24 to 53 years and assessed sleep quality with the St. Mary's Hospital Sleep Questionnaire (SMHSQ) and the Space Aeromedicine Fatigue Checklist.<sup>75</sup>

In another study, glycine improved subjects' sleep efficiency, reduced difficulty in falling asleep, and enhanced sleep satisfaction. This study used both objective measures of sleep quality, including polysomnographic tests and the Visual Analog Scale (VAS), as well as subjective measures of sleep, including the SMHSQ. Each measure suggested that daytime sleepiness improved and that glycine helped with overall sleep quality.<sup>76</sup>

A dose of 31 grams of glycine per day has been shown to be associated with no serious side effects.<sup>77</sup> The pleiotropic and overall health benefits of glycine make it a valuable supplement, even at doses lower than those required to achieve specific sleep benefits.

Glycine has also been shown to improve memory. A 1999 double-blind study showed that compared to younger individuals, middle-aged men had poorer verbal episode memory recall, sustained, focused, or divided attention. However, glycine supplementation significantly improved episodic memory retrieval in both the young and the middle-aged subjects. Unlike other cognitive enhancing supplements, glycine has no stimulant properties or mood effects.<sup>78</sup>

#### Pyridoxyl-5-Phosphate

Pyridoxal-5-Phosphate, or P5P, is the active metabolite of vitamin B6. There are three forms of vitamin B6 found in the diet or in supplements that are usually found in the form of hydrochloride salts – pyridoxine, pyridoxamine and pyridoxal.<sup>79</sup> Though to take effect, pyridoxine and pyridoxamine need to be converted to their active B6 form,

P5P, age and impaired liver function can hinder this conversion.<sup>80</sup> P5P supplementation bypasses the need for this conversion and allows for more immediate benefits. Studies have shown that P5P impacts aspects of sleep. For instance, compared to those taking a placebo, college students who took P5P before bed reported higher levels of dream vividness and emotionality. According to the researchers conducting the study, these results may have been due to vitamin B6-induced cortical arousal during periods of REM sleep.<sup>81</sup>

Any dose of pyridoxine ranging from 25 to 100 mg is considered adequate for neurotransmitter production to support sleep.

Vitamin B6 is a co-factor for a host of enzymatic reactions and thus plays a role in a multitude of functions. For instance, adequate levels of B6 are essential for promoting and maintaining mood, pain perception, and keeping inflammation and inflammatory markers, such as c-reactive protein (CRP), at normal levels.<sup>82,83</sup>

Deficiencies in vitamin B6 result in less methylation of the genes that produce nitric oxide, which, in turn, can trigger a migraine.<sup>84</sup> Vitamin B6 supplementation has also been shown to effectively reduce headache severity and the duration of migraine attacks. Given that nitric oxide deficiency can cause artery vasodilation and that vitamin B6 helps to control nitric oxide availability in the cell, it is perhaps not surprising that B6 supplementation can help in overcoming headaches.

### *Magnesium*

Magnesium is involved in over 300 enzyme-related biochemical processes and appears to influence sleep in a variety of ways. Those who are deficient in magnesium are more likely to have abnormal EEG readings during sleep, more nocturnal awakenings, less time spent in stage 5 REM sleep, and self-reports of poor sleep quality.<sup>85</sup>

On the other hand, those taking dietary magnesium supplements are more likely to experience better sleep efficiency, the ability to fall asleep faster, and the ability to stay asleep longer, which may be related to the ability of magnesium to reduce cortisol levels and inflammatory stress and to enhance melatonin levels.<sup>86,87</sup> Magnesium supplementation is associated with reversals in exercise intolerance that are observed in chronically sleep-deprived individuals<sup>88</sup> as well as the restoration of normal EEG patterns during sleep.<sup>89</sup>

Magnesium is involved not only in sleep but in a variety of aspects of health. One important way that magnesium improves health is by reducing CRP levels. CRP is a general indicator of inflammation in the body, and higher levels of CRP are associated with a higher risk of developing degenerative disease.<sup>90,91</sup>

Overall systemic inflammation caused by Magnesium deficiency will lead to sleep disturbances and supplementation with Magnesium lowers key inflammatory cytokine molecules, CRP, TNF- $\alpha$ , and IL-6.

### *Melatonin*

Melatonin is a hormone produced by the pineal gland that helps to control our body's biorhythms and thereby regulates sleep.<sup>92</sup> It has become one of the most frequently used non-prescription sleep aids. Melatonin helps to promote total sleep time and recovery from jet lag fatigue, and can help balance the circadian rhythm disruption that occurs with rotating shift work.<sup>93</sup> Mounting evidence

suggests that melatonin can increase sleep efficiency, reduce the time it takes for people to fall asleep, and increase total sleep duration.<sup>94,95,96</sup> Melatonin levels decline with age, which is believed to contribute to age-related sleep disorders and age-related diseases.<sup>97</sup>

A comprehensive meta-analysis was recently performed to assess the safety of efficacy of melatonin in children with sleep and neurodevelopmental disorders and found that melatonin is both safe and effective in these youth populations.<sup>99</sup> The Canadian Pediatric Society suggest that the best melatonin dosage for children over the age of 4 is 2.5 to 3 mg, whereas 1 mg of melatonin is recommended for infants and 5 mg for adolescents.<sup>100</sup> Additional research has shown that the response to 5 mg and 10 mg of melatonin does not differ significantly.<sup>101</sup>

Other benefits of melatonin are that it has potent antioxidant properties,<sup>102</sup> lowers inflammatory markers, and is an immune modulator.<sup>103,104</sup> It also contributes to healthy cardiovascular function,<sup>105</sup> plays a role in eye health,<sup>106</sup> and impacts fat and glucose metabolism.<sup>107</sup> As a powerful free radical scavenger, melatonin can directly remove excess free radicals produced during episodes of oxidative stress and can favorably change antioxidant gene expression.<sup>108</sup>

### References

1. Benington JH, Heller HC. Restoration of brain energy metabolism as the function of sleep. *Prog Neurobiol.* 1995;45(4):347-360.
2. Berger RJ, Phillips NH. Energy conservation and sleep. *Behav Brain Res.* 1995;69(1-2):65-73.
3. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. *Science.* 2013;342(6156):373-377. doi:10.1126/science.1241224
4. Siegel JM. Sleep viewed as a state of adaptive inactivity. *Nat Rev Neurosci.* 2009;10(10):747-753. doi:10.1038/nrn2697
5. HHS. 1 in 3 adults don't get enough sleep: A good night's sleep is critical for good health. Centers for Disease Control and Prevention (CDC). <https://www.cdc.gov/media/releases/2016/p0215-enough-sleep.html>. Published 2016.
6. Akerstedt T, Philip P, Capelli A, Kecklund G. Sleep loss and accidents--work hours, life style, and sleep pathology. *Prog Brain Res.* 2011;190:169-188. doi:10.1016/B978-0-444-53817-8.00011-6
7. Wade AG. The societal costs of insomnia. *Neuropsychiatr Dis Treat.* 2010;7:1-18. doi:10.2147/NDT.S15123
8. Leger D, Massuel M-A, Metlaine A. Professional correlates of insomnia. *Sleep.* 2006;29(2):171-178.
9. Malhotra RK. Neurodegenerative disorders and sleep. *Sleep Med Clin.* 2018;13(1):63-70. doi:10.1016/j.jsmc.2017.09.006
10. Shi L, Chen S-J, Ma M-Y, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. *Sleep Med Rev.* 2018;40:4-16. doi:10.1016/j.smrv.2017.06.010
11. Kawakami N, Takatsuka N, Shimizu H. Sleep disturbance and onset of type 2 diabetes. *Diabetes Care.* 2004;27(1):282-283.
12. Bassetti CL. Sleep and stroke. *Semin Neurol.* 2005;25(1):19-32. doi:10.1055/s-2005-867073
13. Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. *Eur J Prev Cardiol.* 2014;21(1):57-64. doi:10.1177/2047487312460020
14. Um YH, Hong S-C, Jeong J-H. Sleep problems as predictors in attention-hyperactivity disorder: causal mechanisms, consequences and treatment. *Clin Psychopharmacol Neurosci.* 2017;15(1):9-18. doi:10.9758/cpn.2017.15.1.9
15. Li Y, Zhang X, Winkelman JW, et al. Association between insomnia symptoms and mortality: a prospective study of U.S. men. *Circulation.*

- 2016;95(17):e3554. doi:10.1097/MD.00000000000035542014;129(7):737-746. doi:10.1161/CIRCULATIONAHA.113.004500
16. Lin Y-K, Lin G-Y, Lee J-T, et al. Associations between sleep quality and migraine frequency: A cross-sectional case-control study. *Medicine (Baltimore)*. 2017;96(12):e5282. doi:10.1097/MD.0000000000000528
17. Wolk R, Gami AS, Garcia-Touchard A, Somers VK. Sleep and cardiovascular disease. *Curr Probl Cardiol*. 2005;30(12):625-662. doi:10.1016/j.cpcardiol.2005.07.002
18. Malhotra A, Loscalzo J. Sleep and cardiovascular disease: an overview. *Prog Cardiovasc Dis*. 2009;51(4):279-284. doi:10.1016/j.pcad.2008.10.004
19. Nagai, M, Hoshida, S, & Kario K. Sleep duration as a risk factor for cardiovascular disease - a review of the recent literature. *Curr Cardiol Rev*. 2010;6(1):54-61.
20. Lao X et al. Sleep quality, sleep duration, and the risk of coronary heart disease: A prospective cohort study with 60,586 adults. *J Clin Sleep Med*. 2018;14(1):109-117.
21. Grandner, MA, Jackson, NJ, Pak, VM, & Gehrman P. Sleep disturbance is associated with cardiovascular and metabolic disorders. *J Sleep Res*. 2012;21(4):427-433.
22. Patyar S, Patyar RR. Correlation between Sleep Duration and Risk of Stroke. *J Stroke Cerebrovasc Dis*. 2015;24(5):905-911. doi:10.1016/j.jstrokecerebrovasdis.2014.12.038
23. Koo DL, Nam H, Thomas RJ, Yun C-H. Sleep Disturbances as a Risk Factor for Stroke. *J stroke*. 2018;20(1):12-32. doi:10.5853/jos.2017.02887
24. Sharma S, Culebras A. Sleep apnoea and stroke. *Stroke Vasc Neurol*. 2016;1(4):185-191. doi:10.1136/svn-2016-0000038
25. Ma C, Pavlova M, Liu Y, et al. Probable REM sleep behavior disorder and risk of stroke: A prospective study. *Neurology*. 2017;88(19):1849-1855. doi:10.1212/WNL.00000000000008902
26. Phua CS, Jayaram L, Wijeratne T. Relationship between Sleep Duration and Risk Factors for Stroke. *Front Neurol*. 2017;8:392. doi:10.3389/fneur.2017.00392
27. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JAHR. Effect of 1 night of total sleep deprivation on cerebrospinal fluid beta-amyloid 42 in healthy middle-aged men: a randomized clinical trial. *JAMA Neurol*. 2014;71(8):971-977. doi:10.1001/jamaneurol.2014.1173
28. Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease. *Nat Rev Neurol*. 2015;11(8):457-470. doi:10.1038/nrneurol.2015.119
29. Rudnicka AR, Nightingale CM, Donin AS, et al. Sleep Duration and Risk of Type 2 Diabetes. *Pediatrics*. 2017;140(3). doi:10.1542/peds.2017-0338
30. Shan Z, Ma H, Xie M, et al. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. *Diabetes Care*. 2015;38(3):529-537. doi:10.2337/dc14-2073
31. Tan X, Chapman CD, Cedernaes J, Benedict C. Association between long sleep duration and increased risk of obesity and type 2 diabetes: A review of possible mechanisms. *Sleep Med Rev*. 2018;40:127-134. doi:10.1016/j.smrv.2017.11.001
32. Dutil C, Chaput J-P. Inadequate sleep as a contributor to type 2 diabetes in children and adolescents. *Nutr Diabetes*. 2017;7(5):e266. doi:10.1038/nutd.2017.19
33. Lecube A, Romero O, Sampol G, et al. Sleep biosignature of Type 2 diabetes: a case-control study. *Diabet Med*. 2017;34(1):79-85. doi:10.1111/dme.13161
34. Lee SWH, Ng KY, Chin WK. The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: A systematic review and meta-analysis. *Sleep Med Rev*. 2017;31:91-101. doi:10.1016/j.smrv.2016.02.001
35. Zhu B, Hershberger PE, Kapella MC, Fritschi C. The relationship between sleep disturbance and glycaemic control in adults with type 2 diabetes: An integrative review. *J Clin Nurs*. 2017;26(23-24):4053-4064. doi:10.1111/jocn.13899
36. Reutrakul S, Mokhlesi B. Obstructive Sleep Apnea and Diabetes: A State of the Art Review. *Chest*. 2017;152(5):1070-1086. doi:10.1016/j.chest.2017.05.009
37. Walsh JK, Coulouvrat C, Hajak G, et al. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). *Sleep*. 2011;34(8):997-1011. doi:10.5665/SLEEP.1150
38. Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. *Headache*. 2005;45(7):904-910. doi:10.1111/j.1526-4610.2005.05159.x
39. Sahota P. Morning headaches in patients with sleep disorders. *Sleep Med*. 2003;4(5):377.
40. Seidel S, Hartl T, Weber M, et al. Quality of sleep, fatigue and daytime sleepiness in migraine - a controlled study. *Cephalalgia*. 2009;29(6):662-669. doi:10.1111/j.1468-2982.2008.01784.x
41. Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. *Pain*. 1993;53(1):65-72.
42. van Oosterhout W, van Someren E, Schoonman GG, et al. Chronotypes and circadian timing in migraine. *Cephalalgia*. 2018;38(4):617-625. doi:10.1177/0333102417698953
43. Spierings EL, Ranke AH, Honkoop PC. Precipitating and aggravating factors of migraine versus tension-type headache. *Headache*. 2001;41(6):554-558.
44. Kelman L. The triggers or precipitants of the acute migraine attack. *Cephalalgia*. 2007;27(5):394-402. doi:10.1111/j.1468-2982.2007.01303.x
45. Hvolby A. Associations of sleep disturbance with ADHD: implications for treatment. *Atten Defic Hyperact Disord*. 2015;7(1):1-18. doi:10.1007/s12402-014-0151-0
46. Snitselaar MA, Smits MC, van der Heijden KB, Spijker J. Sleep and Circadian Rhythmicity in Adult ADHD and the Effect of Stimulants. *J Atten Disord*. 2017;21(1):14-26. doi:10.1177/1087054713479663
47. Peppers KH, Eisbach S, Atkins S, Poole JM, Derouin A. An Intervention to Promote Sleep and Reduce ADHD Symptoms. *J Pediatr Health Care*. 2016;30(6):e43-e48. doi:10.1016/j.pedhc.2016.07.008
48. Morash-Conway J, Gendron M, Corkum P. The role of sleep quality and quantity in moderating the effectiveness of medication in the treatment of children with ADHD. *Atten Defic Hyperact Disord*. 2017;9(1):31-38. :675-685. doi:10.1007/s12402-016-0204-7
49. Everitt H, Baldwin DS, Stuart B, et al. Antidepressants for insomnia in adults. *Cochrane database Syst Rev*. 2018;5:CD010753. doi:10.1002/14651858.CD010753.pub2
50. Lu X-M, Zhu J-P, Zhou X-M. The effect of benzodiazepines on insomnia in patients with chronic obstructive pulmonary disease: a meta-analysis of treatment efficacy and safety. *Int J Chron Obstruct Pulmon Dis*. 2016;11:675-685. doi:10.2147/COPD.S98082
51. Asnis GM, Thomas M, Henderson MA. Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians. *Int J Mol Sci*. 2015;17(1). doi:10.3390/ijms17010050
52. Lie JD, Tu KN, Shen DD, Wong BM. Pharmacological Treatment of Insomnia. *P T*. 2015;40(11):759-771.
53. Franco L, Sanchez C, Bravo R, Rodriguez A, Barriga C, Juanez JC. The sedative effects of hops (*Humulus lupulus*), a component of beer, on the activity/rest rhythm. *Acta Physiol Hung*. 2012;99(2):133-139. doi:10.1556/APhysiol.99.2012.2.6
54. Ross SM. Sleep disorders: a single dose administration of valerian/hops fluid extract (dormeesan) is found to be effective in improving sleep. *Holist Nurs Pract*. 2009;23(4):253-256. doi:10.1097/HNP.0b013e3181aed09d
55. Dimpfel W, Suter A. Sleep improving effects of a single dose administration of a valerian/hops fluid extract - a double blind, randomized, placebo-controlled sleep-EEG study in a parallel design using electrohypnograms. *Eur J Med Res*. 2008;13(5):200-204.
56. Koetter U, Schrader E, Kaufeler R, Brattstrom A. A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. *Phytother Res*. 2007;21(9):847-851. doi:10.1002/ptr.2167
57. Schellenberg R, Sauer S, Abourashed EA, Koetter U, Brattstrom A. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. *Planta Med*. 2004;70(7):594-597. doi:10.1055/s-2004-827180
58. Schmitz M, Jackel M. [Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with a hops-valerian preparation and a benzodiazepine drug]. *Wien Med Wochenschr*. 1998;148(13):291-298.
59. Muller-Limmroth W, Ehrenstein W. [Experimental studies of the effects of Seda-Kneipp on the sleep of sleep disturbed subjects; implications for the treatment of different sleep disturbances (author's transl)]. *Med Klin*. 1977;72(25):1119-1125.
60. Franco L, Sanchez C, Bravo R, et al. The sedative effect of non-alcoholic beer in healthy female nurses. *PLoS One*. 2012;7(7):e37290. doi:10.1371/journal.pone.0037290
61. Dietz BM, Kang Y-H, Liu G, et al. Xanthohumol isolated from *Humulus lupulus* inhibits menadione-induced DNA damage through induction of quinone reductase. *Chem Res Toxicol*. 2005;18(8):1296-1305. doi:10.1021/tx050058x
62. Xin G, Wei Z, Ji C, et al. Xanthohumol isolated from *Humulus lupulus* prevents thrombosis without increased bleeding risk by inhibiting platelet activation and mtDNA release. *Free Radic Biol Med*. 2017;108:247-257. doi:10.1016/j.freeradbiomed.2017.02.018
63. Plazar J, Zegura B, Lah TT, Filipic M. Protective effects of xanthohumol against the genotoxicity of benzo(a)pyrene (BaP), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and tert-butyl hydroperoxide (t-BOOH) in HepG2 human hepatoma cells. *Mutat Res*. 2007;632(1-2):1-8. doi:10.1016/j.mrgentox.2007.03.013
64. Oxman AD, Flottorp S, Havelrud K, et al. A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia. *PLoS One*. 2007;2(10):e1040. doi:10.1371/journal.pone.0001040
65. Pallesen S, Bjorvatn B, Nordhus IH, Skjerve A. [Valerian as a sleeping aid?]. *Tidsskr Nor Laegeforen*. 2002;122(30):2857-2859.
66. Morris CA, Avorn J. Internet marketing of herbal products. *JAMA*. 2003;290(11):1505-1509. doi:10.1001/jama.290.11.1505
67. Ni X, Shergis JL, Guo X, et al. Updated clinical evidence of Chinese herbal medicine for insomnia: a systematic review and meta-analysis of randomized controlled trials. *Sleep Med*. 2015;16(12):1462-1481. doi:10.1016/j.sleep.2015.08.012
68. Rodriguez Villanueva J, Rodriguez Villanueva L. Experimental and clinical pharmacology of ziziphos jujuba mills. *Phytother Res*. 2017;31(3):347-365. doi:10.1002/ptr.5759
69. Shergis JL, Ni X, Sarris J, et al. Ziziphos spinosa seeds for insomnia: A review of chemistry and psychopharmacology. *Phytotherapy*. 2017;34:38-43. doi:10.1016/j.phymed.2017.07.004
70. Hsieh MT, Chen HC, Kao HC, Shibuya T. Suanzaorentang, and anxiolytic Chinese medicine, affects the central adrenergic and serotonergic systems in rats. *Proc Natl Sci Coun Repub China B*. 1986;10(4):263-268.
71. Chen HC, Hsieh MT. Clinical trial of suanzaorentang in the treatment of insomnia. *Clin Ther*. 1985;7(3):334-337.
72. Kwon H, Jung IH, Yi JH, et al. The Seed of Ziziphos jujuba var. spinosa Attenuates Alzheimer's Disease-Associated Hippocampal Synaptic Deficits through BDNF/TrkB Signaling. *Biol Pharm Bull*. 2017;40(12):2096-2104. doi:10.1248/bpb.b17-00378
73. Chase MH, Soja PJ, Morales FR. Evidence that glycine mediates the postsynaptic potentials that inhibit lumbar motoneurons during the atonia of active sleep. *J Neurosci*. 1989;9(3):743-751.
74. Soja PJ. Glycine-mediated postsynaptic inhibition is responsible for REM sleep atonia. *Sleep*. 2008;31(11):1483-1486.
75. Inagawa K et al. Subjective effects of glycine ingestion before bedtime on sleep quality. *Sleep Biol Rythm*. 2006;4:75-77.
76. Yamadera W et al. Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes. *Sleep Biol Rhythm*. 2007;5:126-131.
77. Inagawa K et al. Assessment of acute adverse events of glycine ingestion at a high dose in human volunteers. *J Urban Living Heal Assoc*. 2006;50:27-32.

78. File SE, Fluck E, Fernandes C. Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults. *J Clin Psychopharmacol.* 1999;19(6):506-512.
79. Johansson S, Lindstedt S, Tiselius HG. Metabolic interconversions of different forms of vitamin B6. *J Biol Chem.* 1974;249(19):6040-6046.
80. Russell RM. Factors in aging that effect the bioavailability of nutrients. *J Nutr.* 2001;131(4 Suppl):1359S-61S. doi:10.1093/jn/131.4.1359S
81. Ebben M, Lequerica A, Spielman A. Effects of pyridoxine on dreaming: a preliminary study. *Percept Mot Skills.* 2002;94(1):135-140. doi:10.2466/pms.2002.94.1.135
82. Morris MS, Sakakeeny L, Jacques PF, Picciano MF, Selhub J. Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status. *J Nutr.* 2010;140(1):103-110. doi:10.3945/jn.109.114397
83. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. *Circulation.* 2001;103(23):2788-2791.
84. Sadeghi O, Nasiri M, Maghsoudi Z, Pahlavani N, Rezaie M, Askari G. Effects of pyridoxine supplementation on severity, frequency and duration of migraine attacks in migraine patients with aura: A double-blind randomized clinical trial study in Iran. *Iran J Neurol.* 2015;14(2):74-80.
85. Popoviciu L et al. *Clinical and Polysomnographic Researches in Patients with Sleep Disorders Associated with Magnesium Deficiencies.* London: John Libbey; 1991.
86. Abbasi B, Kimiagar M, Sadeghniaat K, Shirazi MM, Hedayati M, Rashidkhani B. The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. *J Res Med Sci.* 2012;17(12):1161-1169.
87. Nielson, FH, Johnson, LK, Zeng H. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor sleep quality. *Magesium Res.* 2010;23(4):158-168.
88. Tanabe K, Yamamoto A, Suzuki N, et al. Efficacy of oral magnesium administration on decreased exercise tolerance in a state of chronic sleep deprivation. *Jpn Circ J.* 1998;62(5):341-346.
89. Held K, Antonijevic IA, Kunzel H, et al. Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. *Pharmacopsychiatry.* 2002;35(4):135-143. doi:10.1055/s-2002-33195
90. McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. *Ann N Y Acad Sci.* 2004;1035:104-116. doi:10.1196/annals.1332.007
91. Dibaba DT, Xun P, He K. Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review. *Eur J Clin Nutr.* 2014;68(4):510-516. doi:10.1038/ejcn.2014.7
92. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. *Ann Pharmacother.* 1998;32(6):680-691. doi:10.1345/aph.17111
93. Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of the melatonin system in the control of sleep: therapeutic implications. *CNS Drugs.* 2007;21(12):995-1018. doi:10.2165/00023210-200721120-00004
94. Pevet P, Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. *J Physiol Paris.* 2011;105(4-6):170-182. doi:10.1016/j.jphysparis.2011.07.001
95. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. *Dev Med Child Neurol.* 2011;53(9):783-792. doi:10.1111/j.1469-8749.2011.03980.x
96. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. *Sleep Med Rev.* 2005;9(1):41-50. doi:10.1016/j.smr.2004.06.004
97. Karasek M. Melatonin, human aging, and age-related diseases. *Exp Gerontol.* 2004;39(11-12):1723-1729. doi:10.1016/j.exger.2004.04.012
98. Ebrahimi-Monfared M, Sharafkhan M, Abdolrazaghnejad A, Mohammadbeigi A, Faraji F. Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. *Restor Neurol Neurosci.* 2017;35(4):385-393. doi:10.3233/RNN-160704
99. Abdelgadir, IS, Gordon, MA, & Akobeng A. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: A systematic review and meta-analysis. *Drug Ther (NY).* 2018;103(12):1163-1167.
100. Janjua I, Goldman RD. Sleep-related melatonin use in healthy children. *Can Fam Physician.* 2016;62(4):315-317.
101. Parker A, Beresford B, Dawson V, et al. Oral melatonin for non-respiratory sleep disturbance in children with neurodisabilities: systematic review and meta-analyses. *Dev Med Child Neurol.* February 2019. doi:10.1111/dmcn.14157
102. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. *J Pineal Res.* 1993;14(4):151-168.
103. Mayo JC, Sainz RM, Tan D-X, et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. *J Neuroimmunol.* 2005;165(1-2):139-149. doi:10.1016/j.jneuroim.2005.05.002
104. Carrillo-Vico A, Reiter RJ, Lardone PJ, et al. The modulatory role of melatonin on immune responsiveness. *Curr Opin Investig Drugs.*
105. Bielli A, Scioli MC, Mazzaglia D, Doldo E, Orlandi A. Antioxidants and vascular health. *Life Sci.* 2015;143:209-216. doi:10.1016/j.lfs.2015.11.012
106. Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP, Rosenstein RE. Melatonin in the eye: implications for glaucoma. *Exp Eye Res.* 2007;84(6):1021-1030. doi:10.1016/j.exer.2006.10.018
107. Kozirog M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. *J Pineal Res.* 2011;50(3):261-266. doi:10.1111/j.1600-079X.2010.00835.x
108. Mayo JC, Sainz RM, Antoli I, Herrera F, Martin V, Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. *Cell Mol Life Sci.* 2002;59(10):1706-1713.